drugset / Trial / NCT00940641

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

NCT00940641

Phase 1 Suspended 8 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-label

Summary

The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose

Timeline

Start
2009-08
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7325 Small molecule Intravenous

Indications

No indication recorded.